Fidia S.p.A. (BIT:FDA)
Italy
· Delayed Price · Currency is EUR | Market Cap | 819.50K |
| Revenue (ttm) | 21.13M |
| Net Income (ttm) | -2.19M |
| Shares Out | 14.90M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,729,453 |
| Average Volume | 1,476,442 |
| Open | 0.0559 |
| Previous Close | 0.0550 |
| Day's Range | 0.0529 - 0.0568 |
| 52-Week Range | 0.0500 - 1.0600 |
| Beta | 0.03 |
| RSI | 11.46 |
| Earnings Date | Mar 13, 2026 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
What's Going On With Iovance Biotherapeutics Stock On Friday?
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) stock is trading higher on Friday, with no news to justify the movement. Investors should note the company’s short interest sits as high as 39.6%, with a m...
FDA reversals leave investors worrying about the fates of other experimental drugs
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet
(RTTNews) - The biotech sector delivered a mix of regulatory milestones, strategic deals, corporate restructuring and clinical trial developments across therapeutic areas such as hypothalamic obesity,...
Halozyme Says J&J Wins FDA Approval For Tecvayli, Darzalex Faspro Combo In Multiple Myeloma
(RTTNews) - Halozyme Therapeutics Inc. (HALO) on Friday said Johnson & Johnson has received approval from the U.S. Food and Drug Administration for Tecvayli in combination with Darzalex Faspro to trea...
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overal...
FDA Roundup: First-Line Hernexeos, Weekly Yuviwel, Expanded Palynziq & Sogroya Indications
(RTTNews) - The FDA handed out a string of approvals in late February and early March, granting regulatory clearances across several therapeutic areas - from oncology and rare genetic disorders to gro...
Outlook Therapeutics Updates FDA Path For ONS-5010 Following Type A Meeting
(RTTNews) - Outlook Therapeutics, Inc. (OTLK) announced that it recently held a Type A meeting with the U.S. FDA to discuss the Complete Response Letter (CRL) issued in December 2025 for its Biologics...
uniQure (QURE) Faces FDA Demand for Phase 3 Trial for Huntington's Drug
uniQure (QURE) Faces FDA Demand for Phase 3 Trial for Huntington's Drug
Outlook Therapeutics (OTLK) Advances Towards FDA Approval for ONS-5010
Outlook Therapeutics (OTLK) Advances Towards FDA Approval for ONS-5010
Johnson & Johnson (JNJ) Gains FDA Approval for New Multiple Myeloma Treatment
Johnson & Johnson (JNJ) Gains FDA Approval for New Multiple Myeloma Treatment
FDA Approves J&J's Tecvayli for Multiple Myeloma Treatment
FDA Approves J&J's Tecvayli for Multiple Myeloma Treatment
FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease
UniQure needs to run another trial to prove its gene therapy "actually helps people with Huntington's disease," said a senior FDA official.
uniQure's (QURE) Gene Therapy for Huntington's Disease Faces FDA Setback
uniQure's (QURE) Gene Therapy for Huntington's Disease Faces FDA Setback
Johnson & Johnson (JNJ) Gets FDA Nod for Tec-Dara in Multiple Myeloma Treatment
Johnson & Johnson (JNJ) Gets FDA Nod for Tec-Dara in Multiple Myeloma Treatment
Trust in CDC, FDA, NIH shrinks: Survey
A new poll published Thursday found that Americans have lost trust in federal health institutions and are more likely to say they trust independent, professional medical organizations when it comes to...
FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial
FDA official says uniQure's Huntington's gene therapy trial lacked proof of slowing disease, calls for randomized placebo-controlled study. ... Full story available on Benzinga.com
‘Usually everybody loves money’: Trump’s FDA chief to start giving bonuses for faster drug reviews
The FDA lost about 20% of its workforce after Trump took office last year. Now it wants to shrink approvals from as long as 29 months to as low as six.
UniQure (QURE) Faces FDA Hurdle for Huntington's Disease Therapy
UniQure (QURE) Faces FDA Hurdle for Huntington's Disease Therapy
SeaStar Medical Completes FDA Enrollment Requirement For SAVE Registry In Pediatric AKI
(RTTNews) - SeaStar Medical Holding Corporation (ICU) announced that it has completed the FDA-required enrollment for the SAVE Surveillance Registry, a key post-approval study evaluating the safety of...
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70...
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected earl...
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
Zepbound ® (tirzepatide) KwikPen ® for single-patient use available from Lilly at $449 across all doses through the Lilly Employer Connect platform, with reduced cost-share pricing available to employ...
Estrogen patches harder to find as FDA pushes hormone therapy
Estrogen patches, one of the most common forms of hormone therapy for women, are becoming harder to find, and some manufacturers say a recent action by Health and Human Services (HHS) Secretary Robert...
FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial
PepGen (PEPG) shifts focus to DM1 but faces a fresh FDA roadblock. Clinical data, analyst ratings, and technical support levels inside. ... Full story available on Benzinga.com
Granules India subsidiary receives US FDA EIR with NAI status for Virginia facility
Granules India Limited announced that its US step-down subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) status from the...